文献速递消化系统肿瘤

一线氟嘧啶联合贝伐珠单抗后伊立替康增量对比初始氟嘧啶、伊立替康和贝伐珠单抗治疗转移性结直肠癌患者的最终生存和符合方案分析:随机XELAVIRI试验(AIO KRK 0110)

First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
PubMed 文献 · Eur J Cancer · 2022-08-05

XELAVIRI试验比较转移性结直肠癌一线序贯治疗(氟嘧啶+贝伐珠单抗后进展加伊立替康,A组)与初始联合治疗(B组)。全分析集未达到序贯治疗TFS非劣效(HR 0.93;90%CI 0.79-1.10;P=0.482),但>70岁和RAS突变患者达到非劣效;RAS/BRAF野生型中联合治疗所有终点显著优效。

要点

  • 全分析集序贯治疗TFS非劣效未达到(HR 0.93;90%CI 0.79-1.10;P=0.482)。
  • >70岁患者TFS达到非劣效(HR 1.06;90%CI 0.80-1.41;P=0.670)。
  • RAS突变患者TFS达到非劣效(HR 1.12;90%CI 0.87-1.43;P=0.465)。

核心结论

  • 总体人群中序贯治疗对比联合治疗TFS非劣效未达到,但老年患者和RAS突变肿瘤中观察到序贯治疗非劣效。

研究设计与样本

  • 随机开放标签III期XELAVIRI试验(AIO KRK 0110;NCT01249638),全分析集421例患者。

主要发现

  • 全分析集TFS、OS、PFS事件数分别为390(92.6%)、391(92.9%)、357(84.8%),中位随访A组54.2个月 vs B组52.9个月。
  • 全分析集TFS非劣效未达到(HR 0.93;90%CI 0.79-1.10;P=0.482),符合方案集未显示非劣效(HR 0.93;90%CI 0.75-1.13;P=0.433)。
  • >70岁患者TFS达到非劣效(HR 1.06;90%CI 0.80-1.41;P=0.670),RAS突变患者TFS达到非劣效(HR 1.12;90%CI 0.87-1.43;P=0.465)。
  • RAS/BRAF野生型肿瘤中联合治疗在所有终点显著优于序贯治疗。

关键数值与推荐

  • TFS非劣效界值为90%置信边界0.8。
  • TFS使用90%CI,OS和PFS使用95%CI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0.8). Here, we evaluate efficacy in the full analysis set (FAS), the per-protocol set, in addition to age-related and molecular subgroups. METHODS: Median TFS, overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier method and log-rank test. Cox regression models assessed hazard ratios (HRs) and confidence intervals (CIs) (TFS: 90%; OS, PFS: 95%). RESULTS: Of 421 patients, 390 (92.6%), 391 (92.9%) and 357 (84.8%) events for TFS, OS and PFS were observed in the FAS with a median follow-up of 54.2 months (Arm A) versus 52.9 months (Arm B). Non-inferiority of sequential treatment for TFS was missed in the FAS (HR 0.93; 90% CI, 0.79-1.10; P = 0.482) and not shown in the per-protocol set (HR 0.93; 90% CI, 0.75-1.13, P = 0.433). Formal non-inferiority for TFS was observed for patients older than 70 years (HR 1.06; 90% CI, 0.80-1.41; P = 0.670) and patients with RAS mutant tumours (HR 1.12; 90% CI, 0.87-1.43; P = 0.465). In RAS/BRAF wild-type tumours, combination treatment was significantly superior to sequential therapy in all end-points. CONCLUSIONS: In the overall population, XELAVIRI just missed to demonstrate the non-inferiority of sequential compared to combination therapy for TFS. However, the non-inferiority of sequential treatment was observed in elderly patients and RAS mutant tumours. TRIAL REGISTRATION: Trial registration ID (clinicaltrials.gov) NCT01249638.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stahler A, Modest DP, Fischer von Weikersthal L, et al. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). Eur J Cancer. 2022. PMID: 35940054. doi:10.1016/j.ejca.2022.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。